Description: Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Home Page: ascendispharma.com
Tuborg Boulevard 12
Hellerup,
2900
Denmark
Phone:
45 70 22 22 44
Officers
| Name | Title |
|---|---|
| Mr. Jan Moller Mikkelsen | Pres, CEO, Member of Exec. Board & Exec. Director |
| Mr. Michael Wolff Jensen L.L.M. | Sr. VP, Chief Legal Officer & Member of the Exec. Board |
| Dr. Birgitte Volck M.D., Ph.D. | Sr. VP and Head of Clinical Devel. & Endocrinology Rare Diseases Medical Affairs |
| Mr. Scott T. Smith | CFO, Sr. VP & Member of Exec. Board |
| Ms. Lotte Sonderbjerg | Chief Admin. Officer, Sr. VP & Member of the Exec. Board |
| Mr. Peter Rasmussen | VP of Fin. & Principal Accounting Officer |
| Mr. Timothy J. Lee | Sr. Director of Investor Relations |
| Mr. Flemming Steen Jensen | Sr. VP of Product Supply & Quality |
| Dr. Kennett Sprogoe | Sr. VP and Head of Innovation & Research |
| Dr. Jens Sigurd Okkels Ph.D. | Sr. VP of Product Devel. |
Exchange: F
Country: DE
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 14.5235 |
| Price-to-Sales TTM: | 190.8069 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 639 |